Introduction
============

Radiotherapy is a significant adjuvant therapy for breast cancer. Post-mastectomy radiation therapy (PMRT) is always recommended for patients at high risk of recurrence, including those with ≥4 positive axial lymph nodes (ALNs) or a tumor \>5 cm, independent of the nodal status and resection margins ([@b1-ol-0-0-11139]). Adjuvant PMRT has been shown to be extremely useful at improving the survival of high-risk patients, however the benefits and demerits of radiotherapy for breast cancer patients have not been established ([@b2-ol-0-0-11139]).

In 2014, the Early Breast Cancer Trialists\' Collaborate Group published a study on the value of PMRT for breast cancer patients ([@b3-ol-0-0-11139]). The results of that systematic review and meta-analysis of 22 trials demonstrated that PMRT significantly reduced not only the local recurrence rate, but also the breast cancer mortality rate in patients with 1--3 positive ALNs ([@b3-ol-0-0-11139]). The 2015 European Society for Medical Oncology guidelines recommend PMRT for high-risk patients and also suggest the routine use of PMRT for patients with 1--3 positive ALNs ([@b4-ol-0-0-11139]). However, the primary limitation of relevant studies is that they were not randomized control studies. Whether patients with Tumor-Node-Metastasis (TNM) stage of T1-2N1M0 require PMRT remains controversial ([@b5-ol-0-0-11139],[@b6-ol-0-0-11139]). T1-2N1M0 refers to: T1-2, maximum tumor diameter ≤50 mm; N1, micrometastasis (maximum diameter \>0.2 mm, or \>200 tumor cells in a single lymph node tissue section, but the maximum diameter ≤2 mm), 1--3 axillary lymph node metastasis, at least 1 metastatic lesion \>2 mm and transfer (including micro transfer); M0, no distant metastasis ([@b7-ol-0-0-11139]).

In brief, selection of breast cancer patients for PMRT is based on established clinical pathology parameters including the size of the mass and lymph node (LN) status, factors which contribute to the baseline risk of local recurrence ([@b8-ol-0-0-11139]). Nevertheless, a growing body of data has demonstrated the importance of molecular subtypes in treating patients with breast cancer and predicting their prognoses ([@b9-ol-0-0-11139]).

Breast cancer has been demonstrated to be a heterogeneous group of diseases ([@b10-ol-0-0-11139]). Perou *et al* ([@b11-ol-0-0-11139]) first discovered the intrinsic subtypes of breast cancer using bioinformatics analysis of gene expression profiling data. The different molecular subtypes of breast cancer have distinct outcomes, and therefore, breast cancer subtypes have been widely used clinically to select adjuvant systemic therapies and predict patient prognosis ([@b12-ol-0-0-11139]). Comprehensive treatment strategies for breast cancer are based on molecular subtypes, but do not take the individualization of radiotherapy into account ([@b13-ol-0-0-11139]). There is lack of evidence for making firm recommendations about PMRT in the various breast cancer subgroups. The precise relationship between the intrinsic sensitivity of radiotherapy and the molecular subtypes is not yet known and the mechanisms underlying the different responses of the subtypes have not been elucidated.

As the concept and techniques of genotyping continue to develop, molecular typing has become a standardized treatment for the guidance of chemotherapy and endocrine therapy for patients with breast cancer ([@b14-ol-0-0-11139],[@b15-ol-0-0-11139]). These advances raise the question of whether molecular subtypes can be used to predict the response to PMRT and the prognosis. The present study was conducted to assess the effects of PMRT administered to patients with T1-2N1M0 breast cancer and to evaluate the treatment-predictive effect of breast cancer molecular subtypes among patients in the Surveillance, Epidemiology, and End Results (SEER) registry who underwent PMRT.

Patients and methods
====================

### Patient selection

The SEER registry of the National Cancer Institute (USA) is a comprehensive source of information about the occurrence of all new cancer cases among people residing in areas that take part in the SEER program (<https://seer.cancer.gov/>). Of the 181,878 patients with a pathology-based diagnosis of breast cancer between 2010 and 2013, this study restricted analysis to females with a diagnosis of a single primary and malignant breast neoplasm. The median follow-up time was 34 months (range, 0--59 months). Among these, 2,760 patients were treated with radiotherapy (36.97%; PMRT group). The other 4,706 patients (63.03%) were treated without radiotherapy and were classified as no-PMRT group. As the SEER registry began tracking information regarding HER2/neu status in 2010, this date was used as the earliest period for this study. Inclusion criteria for this study were as follows: i) Diagnosis confirmed by histology; ii) female patients with unilateral breast lesions; iii) mastectomy was performed (surgery of primary site variable values of 50--74); and iv) patients were diagnosed with breast cancer defined as T1-2N1M0 stage, according to the 7th American Joint Committee on Cancer (AJCC) cancer staging manual ([@b7-ol-0-0-11139]).

The following cases were excluded: i) Patients diagnosed based on an autopsy or death certificate; ii) patients whose PMRT was uncertain; iii) patients who did not undergo a mastectomy; iv) patients with an unknown molecular subtype, unknown age at diagnosis, unknown year of diagnosis, unknown laterality or unknown survival months; and v) patients who received preoperative systemic therapy (radiotherapy and/or chemotherapy). After these exclusions, a total of 7,466 patients were included in the present study for analysis.

[Table I](#tI-ol-0-0-11139){ref-type="table"} represents the demographic variables of the patients selected: Ethnicity (white, black, others); age at diagnosis (\<55, ≥55 years); year of diagnosis (2010--2013); and marital status (married, unmarried but domestic partner, unmarried, separated, widowed, divorced, unknown). The cancer characteristics included the following: Laterality (left, right); AJCC T-stage (T1, T2); number of positive LNs (1, 2 or 3); histological type (code 8500/3, infiltrating duct carcinoma; code 8520/3, lobular carcinoma; code 8522/3, infiltrating duct and lobular carcinoma; others); histological grade (well differentiated, moderately differentiated, poorly differentiated, undifferentiated, unknown); hormone receptor (HR) status (positive, negative); and human epidermal growth factor receptor 2 (HER2) status (positive, negative) ([Table I](#tI-ol-0-0-11139){ref-type="table"}).

The treatment characteristics of the patients were chemotherapy (yes, no/unknown) and radiotherapy (PMRT group, no-PMRT group). The tumor molecular subtypes were classified as 4 mutually exclusive categories: HR^+^/HER2^−^, HR^−^/HER2^+^, HR^+^/HER2^+^ and HR^−^/HER2^−^ \[defined as triple-negative breast cancer (TNBC)\]. HR^+^ was defined as estrogen receptor (ER)^+^, progesterone receptor (PR)^+^ or borderline positive (those that could not be defined as ER^+^ or PR^+^). In contrast, HR^−^ was defined as ER^−^ and PR^−^. Individuals who had a borderline HER2 status were grouped in another category 'unknown HER2 status' ([@b16-ol-0-0-11139]).

### Statistical analysis

The baseline characteristics of the patients were assessed using a Pearsons χ^2−^test and the aforementioned factors were compared between the PMRT group and the no-PMRT group. The breast cancer-specific survival (BCSS) was extracted from the SEER database. Kaplan-Meier survival curves were generated and the log-rank test was used to identify significant differences between the curves. The prognostic value of PMRT was analyzed by Cox univariate and multivariate regression analyses. Due to the statistical non-significance of the diagnosis year in the univariate regression analysis, this factor was excluded from the multivariate regression analysis. The HR and HER2 statuses of the patients were excluded to avoid a repetition in the analysis. Tests of interaction were used in the Cox multivariate regression analysis. Hazard ratios and 95% confidence intervals (95% CIs) were calculated.

To adjust for potential confounding factors in patients with TNBC, individual propensity score matching (PSM) was performed, in which randomly selected individuals in the PMRT group were paired with comparable individuals in the no-PMRT group. The confounding factors were ethnicity, age, year of diagnosis, marital status, laterality, T stage, positive LN status, histological type, histological grade and chemotherapy. All data analyses were performed using SPSS version 22 (IBM Corp.). All the statistics tests performed were double-sided, and P\<0.05 was considered to indicate a statistically significant difference.

### Outcome measurement

The main endpoint of this study was 5-year BCSS. The patients were recorded as alive or dead in the SEER database, and the option of 'completed months of follow-up' contained the patients survival time in months. The BCSS was calculated from the date of diagnosis to the date of death due to breast cancer or the last follow-up. Patients who were alive were censored on the date of their last visit.

Results
=======

### Clinicopathological characteristics of breast cancer patients

A total of 7,466 T1-2N1M0 breast cancer patients treated with a mastectomy were identified from the SEER database. The clinical characteristics of the patients, and the comparison between the PMRT and no-PMRT group are summarized in [Table I](#tI-ol-0-0-11139){ref-type="table"}. As presented in [Table I](#tI-ol-0-0-11139){ref-type="table"}, 65% (n=4,840) of patients were diagnosed after the age of 55 years. Of these 4,840 patients, 32% received PMRT and 68% did not. Analysis of the data also revealed that 68% (n=5,102) of the patients were HR^+^/HER2^−^, 6% (n=441) were HR^−^/HER2^+^, 14% (n=1,036) were HR^+^/HER2^+^ and 12% (n=887) were HR^−^/HER2^−^ (TNBC). Using the Pearson χ^2−^test, significant differences were observed between the PMRT and the no-PMRT groups with regard to age at diagnosis (P\<0.001), year of diagnosis (P=0.002), marital status (P\<0.001), T stage (P\<0.001), positive LN (P\<0.001), histological grade (P\<0.001), HR status (P\<0.001), HER2 status (P=0.035), subtype (P\<0.001) and chemotherapy (P\<0.001) ([Table I](#tI-ol-0-0-11139){ref-type="table"}). Ethnicity (P=0.500), laterality (P=0.353) and histological type (P=0.150) were not significantly different between the PMRT and no-PMRT group ([Table I](#tI-ol-0-0-11139){ref-type="table"}).

### Prognostic factors

Univariate and multivariate analyses identified the following independent prognostic factors: Ethnicity (P=0.002; P=0.031); age at diagnosis (P=0.006; P=0.028); T stage (P\<0.001; P\<0.001); histological grade (P\<0.001; P\<0.001); molecular subtype (P\<0.001; P\<0.001); and PMRT (P=0.025; P=0.005) ([Table II](#tII-ol-0-0-11139){ref-type="table"}). The multivariate analysis examining subtypes demonstrated that PMRT was an independent prognostic factor for TNBC (Hazard ratio, 1.519; 95% CI, 1.044--2.208; P=0.029) ([Table III](#tIII-ol-0-0-11139){ref-type="table"}).

### Survival analysis

Kaplan-Meier analysis revealed that, among the 4 subtypes of patients with breast cancer, TNBC was associated with the worst BCSS (P\<0.001; [Fig. 1](#f1-ol-0-0-11139){ref-type="fig"}). Patients with T1-2N1M0 breast cancer treated with PMRT showed improved BCSS compared with those not treated with PMRT (P=0.027; [Fig. 2](#f2-ol-0-0-11139){ref-type="fig"}). The Kaplan-Meier analysis of the 4 molecular subtypes revealed that both the HR^+^/HER2^+^ (Hazard ratio, 5.208; 95% CI, 4.141--6.550; P=0.025) and HR^−^/HER2^−^ (Hazard ratio, 3.828; 95% CI, 2.940--4.983; P=0.010) patients benefited from PMRT ([Fig. 3](#f3-ol-0-0-11139){ref-type="fig"}). However, no significant statistical difference was observed in the HR^+^/HER2^−^ (hazard ratio, 0.857; 95% CI, 0.621--1.182; P=0.346) and HR^−^/HER2^+^ (hazard ratio, 0.649; 95% CI, 0.292--1.442; P=0.288).

### PSM analysis

To decrease the influence of potential confounding factors, a PSM analysis was conducted between the PMRT and no-PMRT group of the 4 molecular subtypes of T1-2N1M0 patients. The Kaplan-Meier analysis after PSM demonstrated that only patients with TNBC benefited from PMRT (hazard ratio, 0.6208; 95% CI, 0.4009--0.9615; P=0.025) while patients with the other 3 molecular subtypes did not ([Fig. 4](#f4-ol-0-0-11139){ref-type="fig"}). The PSM analysis assigned 271 patients with T1-2N1M0 TNBC to the PMRT group, matched with 271 patients in the no-PMRT group ([Fig. S1](#SD1-ol-0-0-11139){ref-type="supplementary-material"}). Of the 542 patients with T1-2N1M0 TNBC, no factors differed significantly between the 2 groups ([Table IV](#tIV-ol-0-0-11139){ref-type="table"}).

Discussion
==========

According to the National Comprehensive Cancer Network (USA), after a patient with breast cancer has undergone a total mastectomy with N2/3 ALNs or a T3/4 primary tumor, PMRT is a standard adjuvant therapy ([@b17-ol-0-0-11139]). The application of PMRT for T1-2N1M0 breast cancer remains controversial ([@b18-ol-0-0-11139]--[@b21-ol-0-0-11139]). The St. Gallen Breast Cancer Conference pointed out that \~64% of experts did not recommend PMRT as a routine treatment for T1-2N1M0 breast cancer ([@b22-ol-0-0-11139]). Among these experts, 62% agreed that PMRT can be beneficial for patients with adverse prognostic factors ([@b23-ol-0-0-11139]). In the present study, the molecular subtype of breast cancer was a significant predictor for radiosensitivity.

Breast tumors are heterogeneous, and the heterogeneity determines the strategy for cancer follow-up treatment ([@b24-ol-0-0-11139]). Previous studies have investigated the relationships between histopathological patterns, including tumor size, histological type and histological grade, and therapy and prognosis ([@b25-ol-0-0-11139]). Molecular subtypes of cancer are based on gene expression profiling, which reflects the intrinsic nature of the tumor cells ([@b26-ol-0-0-11139]). Recent studies have demonstrated that these molecular subtypes are associated with different clinical characteristics and outcomes ([@b12-ol-0-0-11139],[@b24-ol-0-0-11139]--[@b29-ol-0-0-11139]). Due to the high cost of gene expression tests, immunohistochemistry, which is a cheaper alternative, was proposed along with criteria set by the expert panel of the 13th St. Gallen International Breast Cancer Conference ([@b23-ol-0-0-11139]). However, very few studies of patients with T1-2N1M0 cancer have evaluated the role of molecular subtyping in guiding decisions regarding radiotherapy after mastectomy.

In the Swedish Breast Cancer Group 91 Radiotherapy trial, radiotherapy showed a trend to improve the BCSS for patients with TNBC; however, this trend did not reach significance ([@b30-ol-0-0-11139]). The results of the present study demonstrated that PMRT can improve the BCSS of patients with T1-2N1M0 TNBC. Of patients with BRCA-1 mutant breast cancer, 60--80% are TNBC, which implies a high association between these types of breast cancer ([@b31-ol-0-0-11139]). When the BRCA-1 gene is mutated, damaged DNA cannot be repaired by homologous recombination, which is the main method for the repair of double-stranded DNA breaks ([@b31-ol-0-0-11139]). The dysfunction or deficiency of BRCA-1 may increase the susceptibility to radiotherapy ([@b31-ol-0-0-11139]).

The main strength of a SEER analysis is that the SEER database has access to a much larger cohort of patients compared with that of a single institution. In the present study, PSM was also conducted to reduce the effects of confounding factors. However, this study had several limitations. Firstly, the SEER registry does not provide any information on the details of treatments such as chemotherapy regimens, HER2-targeted therapy, endocrine therapy or methods of PMRT. In addition, the SEER registry lacks information on the specific positive rates of ER/PR and Ki-67, and therefore, the 4 molecular types examined in this study are only a molecular subtype estimation. Due to HER2 status only being available after 2010 in the SEER database, this resulted in a lack of samples and insufficient follow-up in the present study.

As research on TNBC progresses, patients with the T1-2N1M0 subtype, which has no therapeutic targets to date, may benefit from radiotherapy, although guidelines and current international consensuses do not recommend the routine use of PMRT for patients with this subtype ([@b19-ol-0-0-11139],[@b32-ol-0-0-11139]). Clinical trials should be conducted to validate the effectiveness of radiotherapy after mastectomy in patients with T1-2N1M0 TNBC.

In conclusion, patients with T1-2N1M0 TNBC can benefit from PMRT. Despite limitations, the findings of the current study will help clinicians identify patients with T1-2N1M0 breast cancer who may benefit from PMRT.
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###### 

Clinicopathological characteristics of the patients in PMRT group and no-PMRT group.

  Characteristics                           Cases, n (%)   PMRT, n (%)   No PMRT, n (%)   P-value
  ----------------------------------------- -------------- ------------- ---------------- ---------
  Total                                     7,466 (100)    2,760 (37)    4,706 (63)       
  Ethnicity                                                                               0.500
    White                                   5,699 (76)     2,095 (37)    3,604 (63)       
    Black                                   973 (13)       376 (39)      597 (61)         
    Others                                  794 (11)       289 (36)      505 (64)         
  Age at diagnosis, years                                                                 \<0.001
    \<55                                    2,626 (35)     1,231 (47)    1,395 (53)       
    ≥55                                     4,840 (65)     1,529 (32)    3,311 (68)       
  Year of diagnosis                                                                       0.002
    2010                                    2,032 (27)     685 (34)      1,347 (66)       
    2011                                    1,931 (26)     760 (39)      1,171 (61)       
    2012                                    1,834 (25)     699 (38)      1,135 (62)       
    2013                                    1,669 (22)     616 (37)      1,053 (63)       
  Marital status                                                                          \<0.001
    Married/unmarried or domestic partner   4,152 (56)     1,631(39)     2,521 (61)       
    Never married                           1,153 (15)     442 (38)      711 (62)         
    Unmarried/separated/widowed             1,783 (24)     552 (31)      1,135 (69)       
    Unknown                                 378 (5)        135 (36)      1,053 (64)       
  Laterality                                                                              0.353
    Left                                    3,807 (51)     1,388 (36)    2,419 (64)       
    Right                                   3,659 (49)     1,372 (38)    2,287 (62)       
  T stage                                                                                 \<0.001
    T1                                      2,791 (37)     867 (31)      1,924 (69)       
    T2                                      4,675 (63)     1,893 (40)    2,782 (60)       
  Positive lymph node, n                                                                  \<0.001
    1                                       3,922 (53)     1,189 (30)    2,733 (70)       
    2                                       2,264 (30)     922 (41)      1,342 (59)       
    3                                       1,280 (17)     649 (51)      631 (49)         
  Histological type                                                                       0.150
    IDC                                     5,956 (80)     2,239 (38)    3,717 (62)       
    ILC                                     564 (7)        200 (35)      364 (65)         
    IDC+ILC                                 434 (6)        146 (34)      288 (66)         
    Others                                  512 (7)        175 (34)      337 (66)         
  Histological grade                                                                      \<0.001
    I                                       828 (11)       231 (28)      597 (72)         
    II                                      3,198 (43)     1,111 (35)    2,087 (65)       
    III                                     3,233 (43)     1,337 (41)    1,896 (59)       
    Unknown                                 207 (3)        81 (39)       126 (61)         
  HR status                                                                               \<0.001
    HR^+^                                   6,138 (82)     2,204 (36)    3,934 (64)       
    HR^−^                                   1,328 (18)     556 (42)      772 (58)         
  HER2 status                                                                             0.035
    HER2^+^                                 1,477 (20)     581 (39)      896 (61)         
    HER2^−^                                 5,989 (80)     2,179 (36)    3,810 (64)       
  Subtype                                                                                 \<0.001
    HR^+^/HER2^−^                           5,102 (68)     1,781 (35)    3,321 (65)       
    HR^−^/HER2^+^                           441 (6)        158 (36)      283 (64)         
    HR^+^/HER2^+^                           1,036 (14)     423 (41)      613 (59)         
    HR^−^/HER2^−^                           887 (12)       398 (45)      489 (55)         
  Chemotherapy                                                                            \<0.001
    Yes                                     5,318 (71)     2,462 (46)    2,856 (54)       
    No/unknown                              2,148 (29)     298 (14)      1,850 (86)       

PMRT, post-mastectomy radiotherapy; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; HR, hormone receptor; HER2, human epidermal growth receptor-2.

###### 

Univariate and multivariate analysis to evaluate breast cancer-specific survival according to clinicopathological variables from the SEER database.

                                             Univariate analysis    Multivariate analysis                          
  ------------------------------------------ ---------------------- ----------------------- ---------------------- ---------
  Ethnicity                                                         0.002                                          0.031
    White                                    Reference                                      Reference              
    Black                                    1.380 (1.823--1.823)   0.023                   1.036 (0.778--1.379)   0.811
    Others                                   0.556 (0.349--0.886)   0.014                   0.54 (0.339--0.862)    0.010
  Age at diagnosis, years                                                                                          
    \<55                                     Reference                                      Reference              
    ≥55                                      1.385 (1.098--1.747)   0.006                   1.314 (1.029--1.677)   0.028
  Year of diagnosis                                                 0.690                                          
    2010                                     Reference                                                             
    2011                                     0.89 (0.685--1.156)    0.382                                          
    2012                                     1.065 (0.786--1.444)   0.683                                          
    2013                                     0.945 (0.588--1.518)   0.815                                          
  Marital status                                                    0.009                                          0.204
    Married/unmarried but domestic partner   Reference                                      Reference              
    Unmarried                                1.344 (0.997--1.812)   0.053                   1.217 (0.895--1.654)   0.210
    Separated/widowed                        1.479 (1.156--1.891)   0.002                   1.254 (0.972--1.617)   0.082
    Unknown                                  1.467 (0.932--2.310)   0.098                   1.394 (0.884--2.198)   0.153
  Laterality                                                                                                       
    Left                                     Reference                                                             
    Right                                    0.815 (0.66--1.007)    0.058                                          
  T stage                                                                                                          
    T1                                       Reference                                      Reference              
    T2                                       2.625 (2.011--3.427)   \<0.001                 2.356 (1.796--3.09)    \<0.001
  Positive lymph nodes, n                                           0.267                                          0.202
    1                                        Reference                                      Reference              
    2                                        0.935 (0.73--1.196)    0.590                   0.916 (0.715--1.174)   0.489
    3                                        1.199 (0.91--1.58)     0.197                   1.212 (0.916--1.603)   0.179
  Histological type                                                 0.006                                          0.337
    IDC                                      Reference                                      Reference              
    ILC                                      0.42 (0.241--0.733)    0.002                   0.604 (0.34--1.073)    0.085
    IDC+ILC                                  0.603 (0.353--1.03)    0.064                   0.933 (0.54--1.610)    0.802
    Others                                   0.899 (0.593--1.362)   0.615                   0.848 (0.557--1.292)   0.444
  Histological grade                                                \<0.001                                        \<0.001
    I                                        Reference                                      Reference              
    II                                       1.420 (0.845--2.384)   0.185                   1.264 (0.749--2.133)   0.380
    III                                      3.809 (2.328--6.232)   \<0.001                 2.213 (1.307--3.747)   0.003
    Unknown                                  1.762 (0.731--4.249)   0.207                   1.275 (0.521--3.119)   0.595
  HR status                                                                                                        
    HR^+^                                    Reference                                                             
    HR^−^                                    4.176 (3.382--5.156)   \<0.001                                        
  HER2 status                                                                                                      
    HER2^+^                                  Reference                                                             
    HER2^−^                                  1.361 (1.016--1.823)   0.039                                          
  Subtype                                                           \<0.001                                        \<0.001
    HR^+^/HER2^−^                            Reference                                      Reference              
    HR^−^/HER2^+^                            1.911 (1.263--2.892)   0.002                   1.464 (0.951--2.254)   0.083
    HR^+^/HER2^+^                            0.842 (0.56--1.266)    0.410                   0.711 (0.469--1.08)    0.110
    HR^−^/HER2^−^                            5.208 (4.141--6.550)   \<0.001                 3.828 (2.94--4.983)    \<0.001
  Chemotherapy                                                                                                     
    Yes                                      Reference                                      Reference              
    No/unknown                               1.23 (0.982--1.542)    0.071                   1.518 (1.182--1.949)   0.001
  PMRT                                                                                                             
    Yes                                      Reference                                      Reference              
    No                                       1.294 (1.033--1.622)   0.025                   1.413 (1.112--1.796)   0.005

IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; HR, hormone receptor; HER2, human epidermal growth receptor-2; PMRT, post-mastectomy radiotherapy.

###### 

Multivariate analysis to evaluate breast cancer-specific survival by molecular subtype.

  Subtypes                           Hazard ratio (95% CI)   P-value
  ---------------------------------- ----------------------- ---------
  HR^+^/HER2^−^, PMRT vs. no PMRT    1.189 (0.836--1.692)    0.335
  HR^−^/HER2^+−^, PMRT vs. no PMRT   1.108 (0.429--2.857)    0.833
  HR^+^/HER2^+−^, PMRT vs. no PMRT   2.391 (0.845--6.763)    0.100
  HR^−^/HER2^−^, PMRT vs. no PMRT    1.519 (1.044--2.208)    0.029

PMRT, post-mastectomy radiotherapy; HR, hormone receptor; HER2, human epidermal growth receptor-2.

###### 

Clinicopathological characteristic before and after PSM in patients with triple-negative breast cancer with and without PMRT.

                                            Before PSM   After PSM                                          
  ----------------------------------------- ------------ ----------- -------- --------- ----- ----- ------- -------
  Ethnicity                                                          0.537    0.764                 0.162   0.922
    White                                   286          350                            192   191           
    Black                                   75           99                             51    54            
    Others                                  37           40                             28    26            
  Age at diagnosis, years                                            8.551    0.003                 3.411   0.065
    \<55                                    175          168                            117   96            
    ≥55                                     223          321                            154   175           
  Year of diagnosis                                                  3.37     0.338                 0.785   0.853
    2010                                    97           142                            66    73            
    2011                                    110          129                            81    75            
    2012                                    108          113                            65    61            
    2013                                    83           105                            59    62            
  Marital status                                                     2.93     0.403                 2.583   0.461
    Married/unmarried or domestic partner   228          252                            164   146           
    Never married                           59           83                             37    46            
    Unmarried/separated/widowed             91           126                            57    65            
    Unknown                                 20           28                             13    14            
  Laterality                                                         1.563    0.211                 0.119   0.731
    Left                                    217          246                            146   142           
    Right                                   181          243                            125   129           
  T stage                                                            6.643    0.010                 0       1.000
    T1                                      95           155                            63    63            
    T2                                      303          334                            208   208           
  Positive lymph nodes, n                                            7.984    0.018                 1.598   0.450
    1                                       201          285                            166   152           
    2                                       114          134                            72    84            
    3                                       83           70                             33    35            
  Histologic type                                                    0.581    0.446                 0       1.000
    IDC                                     358          432                            246   246           
    ILC/IDC+ILC/others                      40           57                             25    25            
  Histological grade                                                 11.514   0.003                 1.811   0.404
    I/II                                    34           79                             24    33            
    III                                     352          395                            239   232           
    Unknown                                 12           15                             8     6             
  Chemotherapy                                                       72.69    \<0.001               0.31    0.861
    Yes                                     379          361                            253   254           
    No/Unknown                              19           128                            18    17            

PSM, propensity score matching; PMRT, post-mastectomy radiotherapy; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma.

[^1]: Contributed equally
